Back
Vertex Pharmaceuticals Quote, Financials, Valuation and Earnings
New AI Stock Payouts
Watch this presentation before then!
Buy
60
VRTX
Vertex Pharmaceuticals
Last Price:
355.00
Seasonality Move:
-1.51%
7 Day Trial
ALL ACCESS PASS
$
7
R.I.P. for the American Dream? (Surprising answer inside...)
Go here now for the details.Vertex Pharmaceuticals Price Quote
$355.00
+2.69 (+0.76%)
(Updated: September 21, 2023 at 3:00 PM ET)
Vertex Pharmaceuticals Key Stats
Buy
60
Vertex Pharmaceuticals (VRTX)
is a Buy
Day range:
$352.18 - $358.59
52-week range:
$276.57 - $367.00
Dividend yield:
0%
P/E ratio:
27.48
P/S ratio:
9.64
P/B ratio:
5.88%
Volume:
903.4K
Avg. volume:
818.7K
1-year change:
22.78%
Market cap:
$90.9B
Revenue:
$8.9B
EPS:
$12.95
How Much Does Vertex Pharmaceuticals Make?
-
How Much Are Vertex Pharmaceuticals's Sales Annually?
VRTX Revenues are $8.9B -
How Much Profit Does Vertex Pharmaceuticals's Make A Year?
VRTX net income is $3.3B
Is Vertex Pharmaceuticals Growing As A Company?
-
What Is Vertex Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.14% -
What Is Vertex Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0.12%
Vertex Pharmaceuticals Stock Price Performance
-
Did Vertex Pharmaceuticals Stock Go Up Last Month?
Vertex Pharmaceuticals share price went up by 2.17% last month -
Did VRTX's Share Price Rise Over The Last Year?
VRTX share price rose by 22.78% over the past 1 year
What Is Vertex Pharmaceuticals 52-Week High & Low?
-
What Is Vertex Pharmaceuticals’s 52-Week High Share Price?
Vertex Pharmaceuticals has traded as high as $367.00 over the past 52 weeks -
What Is Vertex Pharmaceuticals’s 52-Week Low Share Price?
Vertex Pharmaceuticals has traded as low as $276.57 over the past 52 weeks
Vertex Pharmaceuticals Price To Free Cash Flow
-
Is Vertex Pharmaceuticals Stock Overvalued?
Vertex Pharmaceuticals is trading at a price to free cash flow ratio of 23.63 -
Is Vertex Pharmaceuticals Stock Undervalued?
Vertex Pharmaceuticals EV to Free Cash Flow ratio is 20.55 -
What Is Vertex Pharmaceuticals’s Price Earnings Growth Ratio?
VRTX PEG ratio is 5.80 -
Is Vertex Pharmaceuticals Trading At A Premium To Earnings?
Vertex Pharmaceuticals EV to EBIT ratio is 18.30
Is It Risky To Buy Vertex Pharmaceuticals?
-
How Much Debt Does Vertex Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Vertex Pharmaceuticals Have?
Cash and short term investments quarterly total is $11.2B -
What Is Vertex Pharmaceuticals’s Book Value Per Share?
Book value per share is 60.01
Is Vertex Pharmaceuticals Cash Flow Positive?
-
What Is VRTX Cash Flow From Operations?
Cash flow from operations (TTM) is $4.1B -
What Is Vertex Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$297.4M -
What Is Vertex Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$2.3B
Vertex Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
VRTX return on invested capital is 24.46% -
What Is Vertex Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 18.74% -
What Is VRTX Return On Equity?
ROE is a measure of profitability and is 24.46%
Vertex Pharmaceuticals Earnings Date & Stock Price
-
What Is Vertex Pharmaceuticals's Stock Price Today?
A single share of VRTX can be purchased today for 352.31 -
What Is Vertex Pharmaceuticals’s Stock Symbol?
Vertex Pharmaceuticals trades on the S&P500 under the ticker symbol: VRTX -
When Is Vertex Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Vertex Pharmaceuticals is scheduled on October 27, 2023 -
When Is VRTX's next ex-dividend date?
Vertex Pharmaceuticals's next ex-dividend date is September 21, 2023 -
How To Buy Vertex Pharmaceuticals Stock?
You can buy Vertex Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Vertex Pharmaceuticals Competitors
-
Who Are Vertex Pharmaceuticals's Competitors?
Below is a list of companies who compete with Vertex Pharmaceuticals or are related in some way:
Vertex Pharmaceuticals Dividend Yield
Data Unavailable
Vertex Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 12.46% | 0.15% |
| Revenue: | 13.52% | 3% |
Analyst Recommendations
| Buy Recommendations: | 14 |
|---|---|
| Hold Recommendations: | 11 |
| Sell Recommendations: | 0 |
| Price Target: | 384.26 |
| Upside from Last Price: | 9.07% |